公开(公告)号：US20240360248A1

公开(公告)日：2024-10-31

申请号：US18684078

申请日：2022-08-17

Applicant: NANOMAB TECHNOLOGY LIMITED

Inventor： Chung Lim WONG ,  Hong Hoi TING

IPC: C07K16/40 ,  G01N33/573 ,  G01N33/68

CPC classification number: C07K16/40 ,  G01N33/573 ,  G01N33/6854 ,  C07K2317/565 ,  C07K2317/569

Abstract: Provided are a set of specific single-domain antibody coding sequences targeting PTK7 and an application thereof. The provided anti-PTK7 single-domain antibody may effectively bind to a PTK7 antigen, which provides a basis for the research and development of drugs targeting PTK7, including radionuclide drug conjugates, antibody drug conjugates, multispecific antibody drugs and so on.

公开(公告)号：US11466085B2

公开(公告)日：2022-10-11

申请号：US16723037

申请日：2019-12-20

Applicant: NANOMAB TECHNOLOGY LIMITED

Inventor： Hong Hoi Ting ,  Chung Lim Wong

IPC: A61P35/00 ,  C07K16/28 ,  A61K39/395 ,  C12N15/63 ,  C07K16/06 ,  C12N15/62 ,  C12N15/85

Abstract: Provided in the present invention are a type of anti-human PD-L1 specific nanobodies and VHH chains thereof, coding sequences of the foregoing nanobodies or VHH chains thereof, corresponding expression vectors and host cells, and a method for producing antibodies.

公开(公告)号：US20200306392A1

公开(公告)日：2020-10-01

申请号：US16624403

申请日：2018-06-20

Applicant: NANOMAB TECHNOLOGY LIMITED

Inventor： Hong Hoi Ting ,  Chung Lim Wong ,  Wenhua Huang

IPC: A61K51/10 ,  C07K16/32 ,  A61K47/68

Abstract: Provided are an anti-Her2 nanobody and a coding sequence and the use thereof. In particular, provided is a nanobody combating human epidermal growth factor receptor-2 (Her2/ERBB2). Disclosed are the nanobody and the a gene sequence encoding the nanobody, a corresponding expression vector and a host cell capable of expressing the nanobody, and a method for producing the nanobody of the present invention and the related use thereof. The present invention may also provide an immunoconjugate of the nanobody and the use thereof, especially the use in the diagnosis and treatment of Her2 positive tumor.

公开(公告)号：US20200276330A1

公开(公告)日：2020-09-03

申请号：US16647467

申请日：2018-09-13

Applicant: NANOMAB TECHNOLOGY LIMITED

Inventor： Hong Hoi TING ,  Chung Lim WONG

IPC: A61K47/68 ,  A61K51/08 ,  A61K49/16 ,  G01N33/68

Abstract: Disclosed is the use of a radiolabeled anti-nanobody in the prognosis and diagnosis of cancers. In particular, disclosed is an immunoconjugate for detecting a PD-L1 molecule. The immunoconjugate comprises the VHH chain of a specific anti-PD-L1 nanobody and a radionuclide, and can be used for non-invasive detecting of expression of the object PD-L1 to be detected. The immunoconjugate of the invention has small size and high specificity, and is suitable for systemic detection which simultaneously targets primary and metastatic tumors, and has high accuracy and low radiation dose.

公开(公告)号：US20230263916A1

公开(公告)日：2023-08-24

申请号：US18047327

申请日：2022-10-18

Applicant: NANOMAB TECHNOLOGY LIMITED

Inventor： Hong Hoi Ting ,  Chung Lim Wong ,  Wenhua Huang

IPC: A61K51/10 ,  A61K47/68 ,  C07K16/32

CPC classification number: A61K51/1051 ,  A61K47/6803 ,  A61K47/6855 ,  C07K16/32 ,  C07K2317/51 ,  C07K2317/92

Abstract: Provided are an anti-Her2 nanobody and a coding sequence and the use thereof. In particular, provided is a nanobody combating human epidermal growth factor receptor-2 (Her2/ERBB2). Disclosed are the nanobody and the a gene sequence encoding the nanobody, a corresponding expression vector and a host cell capable of expressing the nanobody, and a method for producing the nanobody of the present invention and the related use thereof. The present invention may also provide an immunoconjugate of the nanobody and the use thereof, especially the use in the diagnosis and treatment of Her2 positive tumor.

公开(公告)号：US20200148772A1

公开(公告)日：2020-05-14

申请号：US16723037

申请日：2019-12-20

Applicant: NANOMAB TECHNOLOGY LIMITED

Inventor： Hong Hoi Ting ,  Chung Lim Wong

IPC: C07K16/28 ,  C12N15/63 ,  A61K39/395 ,  C12N15/85 ,  C12N15/62 ,  C07K16/06 ,  A61P35/00

Abstract: Provided in the present invention are a type of anti-human PD-L1 specific nanobodies and VHH chains thereof, coding sequences of the foregoing nanobodies or VHH chains thereof, corresponding expression vectors and host cells, and a method for producing antibodies.

公开(公告)号：US12083193B2

公开(公告)日：2024-09-10

申请号：US18047327

申请日：2022-10-18

Applicant: NANOMAB TECHNOLOGY LIMITED

Inventor： Hong Hoi Ting ,  Chung Lim Wong ,  Wenhua Huang

IPC: A61K51/10 ,  A61K47/68 ,  C07K16/32

CPC classification number: A61K51/1051 ,  A61K47/6803 ,  A61K47/6855 ,  C07K16/32 ,  C07K2317/51 ,  C07K2317/92

Abstract: Provided are an anti-Her2 nanobody and a coding sequence and the use thereof. In particular, provided is a nanobody combating human epidermal growth factor receptor-2 (Her2/ERBB2). Disclosed are the nanobody and the a gene sequence encoding the nanobody, a corresponding expression vector and a host cell capable of expressing the nanobody, and a method for producing the nanobody of the present invention and the related use thereof. The present invention may also provide an immunoconjugate of the nanobody and the use thereof, especially the use in the diagnosis and treatment of Her2 positive tumor.

公开(公告)号：US11642418B2

公开(公告)日：2023-05-09

申请号：US16647467

申请日：2018-09-13

Applicant: NANOMAB TECHNOLOGY LIMITED

Inventor： Hong Hoi Ting ,  Chung Lim Wong

IPC: A61K47/68 ,  A61K49/16 ,  A61K51/08 ,  G01N33/68

CPC classification number: A61K47/6849 ,  A61K47/6803 ,  A61K49/16 ,  A61K51/088 ,  G01N33/6872

Abstract: Disclosed is the use of a radiolabeled anti-nanobody in the prognosis and diagnosis of cancers. In particular, disclosed is an immunoconjugate for detecting a PD-L1 molecule. The immunoconjugate comprises the VHH chain of a specific anti-PD-L1 nanobody and a radionuclide, and can be used for non-invasive detecting of expression of the object PD-L1 to be detected. The immunoconjugate of the invention has small size and high specificity, and is suitable for systemic detection which simultaneously targets primary and metastatic tumors, and has high accuracy and low radiation dose.

公开(公告)号：US11517632B2

公开(公告)日：2022-12-06

申请号：US16624403

申请日：2018-06-20

Applicant: NANOMAB TECHNOLOGY LIMITED

Inventor： Hong Hoi Ting ,  Chung Lim Wong ,  Wenhua Huang

IPC: A61K51/10 ,  A61K47/68 ,  C07K16/32

Abstract: Provided are an anti-Her2 nanobody and a coding sequence and the use thereof. In particular, provided is a nanobody combating human epidermal growth factor receptor-2 (Her2/ERBB2). Disclosed are the nanobody and the a gene sequence encoding the nanobody, a corresponding expression vector and a host cell capable of expressing the nanobody, and a method for producing the nanobody of the present invention and the related use thereof. The present invention may also provide an immunoconjugate of the nanobody and the use thereof, especially the use in the diagnosis and treatment of Her2 positive tumor.

公开(公告)号：US20190177416A1

公开(公告)日：2019-06-13

申请号：US16085899

申请日：2017-03-17

Applicant: NANOMAB TECHNOLOGY LIMITED

Inventor： Hong Hoi Ting ,  Chung Lim Wong

IPC: C07K16/28 ,  A61P35/00 ,  C07K16/06 ,  C12N15/85 ,  C12N15/62

CPC classification number: C07K16/2827 ,  A61K39/395 ,  A61P35/00 ,  C07K16/065 ,  C07K16/28 ,  C07K2317/569 ,  C12N15/62 ,  C12N15/63 ,  C12N15/85 ,  C12N2015/8518

Abstract: Provided in the present invention are a type of anti-human PD-L1 specific nanobodies and VHH chains thereof, coding sequences of the foregoing nanobodies or VHH chains thereof, corresponding expression vectors and host cells, and a method for producing antibodies.